- Amazon’s teeny step toward pharmacy disruption
- How patients view copay accumulators
- My $0.02 on generic and biosimilar trends
- Some hospitals seem to be gaming their 340B eligibility
P.S. Please join the nearly 12,000 consumers of my daily commentary and links to neat stuff at @DrugChannels on Twitter. You can also find me on LinkedIn, where I am approaching 19,000 followers.